Ignite Creation Date:
2024-05-06 @ 6:52 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05817201
Status:
RECRUITING
Last Update Posted:
2023-04-18
First Post:
2023-04-03
Brief Title:
Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy
Sponsor:
Taizhou Hospital
Organization:
Taizhou Hospital
Study Overview
Official Title:
A Phase II and III Randomized Multicenter Clinical Study Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to explore the therapeutic efficacy of immune checkpoint inhibitors combined with radical radiotherapy in elderly patients with esophageal cancer
Detailed Description:
Older patients with esophageal cancer are universally intolerant to chemotherapy
This study is performed to explore a non-chemotherapy strategy for elderly esophageal cancer patients
Participants will be treated with Toripalimab monoclonal antibody maintenance versus S-1 combined with radiotherapy intended to explore the efficacy and safety of non-chemotherapy strategy for elderly esophageal cancer patients
This study is performed to explore a non-chemotherapy strategy for elderly esophageal cancer patients
Participants will be treated with Toripalimab monoclonal antibody maintenance versus S-1 combined with radiotherapy intended to explore the efficacy and safety of non-chemotherapy strategy for elderly esophageal cancer patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None